Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 310 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast... April 12, 2021 FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma July 12, 2022 Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix November 25, 2021 From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror March 21, 2024 Load more HOT NEWS Charity ‘looks to the future with renewed optimism’ Talk Cancer: How to have conversations that could save lives How We’re Working to Help People With Cancer Across the World Lung Cancer Treatment Research Enters a New Era
